Mumbai-based Sun Pharma has introduced its global innovative biologic Ilumya (Tildrakizumab) in India for the treatment of moderate-to-seve.

Innovent's Pecondle, a recombinant anti-interleukin-23p19 subunit, receives China NMPA approval to treat moderate-to-severe plaque psoriasis: San Francisco Monday, December 1, 202 ...

Sun Pharma's managing director, Kirti Ganorkar, said Ilumya is already available in 35 countries and has consistently ...

Sun Pharmaceutical Industries on Monday said it has launched its global innovative drug ILUMYA in India for the treatment of ...

“Our study demonstrated in a large real-world population that long-term treatment of up to 5 years with adalimumab in adult patients with psoriasis led to a sustained improvement in the practice of ...

Researchers in China report that global incidence rates of psoriasis rose slightly from 1990 to 2021 and are projected to ...

North America and Western Europe — two wealthier regions of the world — reported the highest incidences and are projected to ...

Sun Pharmaceutical Industries announced the launch of its global innovative drug, ILUMYA (Tildrakizumab) in India for moderate-to-severe plaque psoriasis. A novel biologic treatment, ILUMYA has been ...

Company's immunology franchise demonstrates strong market momentum with preferred status under one of the largest pharmacy benefit managers in the ...

A Johns Hopkins Medicine study involving a dozen people with the inflammatory skin disease hidradenitis suppurativa (HS), ...

A Johns Hopkins Medicine study involving a dozen people with the inflammatory skin disease hidradenitis suppurativa (HS), ...